3: Early clindamycin for bacterial vaginosis in low-risk pregnancy: the PREMEVA1 randomized, multicenter, double-blind, placebo-controlled trial

The treatment of bacterial vaginosis in pregnancy with clindamycin to reduce the risk of infection‐related preterm birth: a response to the Danish Society of Obstetrics and Gynecology guideline group's clinical recommendations

“…The recommendations also fail to incorporate the recent findings that screening and treating of vulvovaginal candidiasis, trichomoniasis (treated appropriately) and BV (treated with CVC) reduced the rate of PTB and low birthweight from 22.3 to 20% in controls to 9.7 and 8.4%, respectively ( p = 0.001) . We argue that the clinical recommendations should be revoked and the PREMEVA1 study should not be used to influence guidelines or clinical recommendations.…”

Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery – a clinical recommendation

“…One study used Nugent scores of 7–10 and candidiasis to define abnormal vaginal microbiota . Only two studies used strict Nugent scores 7–10 . Four studies used Amsel criteria .…”

Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo‐controlled clinical trial

“…Despite the inconsistency of this trial's findings with the two previous hospital-based published trials of oral clindamycin, 7,10 our large trial results are consistent with another large (n = 2869) randomised double-blind trial of oral clindamycin administered early in pregnancy. 26 In an abstract of their study findings, Subtil and colleagues studied French parturients with BV defined by Nugent score and randomised these women to early oral clindamycin or placebo. Like our investigation, they found the rates of preterm birth did not differ between the two groups.…”